Curis Provides Fourth Quarter 2025 Business Update

Curis Provides Fourth Quarter 2025 Business Update Accessibility StatementSkip Navigation Management to host conference call today at 4:30 p.m. ET LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025. Operational Highlights TakeAim Lymphoma Lakshmi Nay ...